Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
4649 | 1749 | 44.4 | 92% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
449 | 3 | FAMILIAL MEDITERRANEAN FEVER//TOLL LIKE RECEPTORS//INFLAMMASOME | 25887 |
543 | 2 | TOLL LIKE RECEPTORS//INNATE IMMUNITY//CPG ODN | 14712 |
4649 | 1 | CPG ODN//CPG MOTIF//CPG DNA | 1749 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | CPG ODN | authKW | 1459238 | 10% | 48% | 173 |
2 | CPG MOTIF | authKW | 1088779 | 6% | 58% | 108 |
3 | CPG DNA | authKW | 914026 | 5% | 55% | 96 |
4 | CPG OLIGODEOXYNUCLEOTIDES | authKW | 878242 | 5% | 59% | 86 |
5 | TLR9 | authKW | 438717 | 5% | 26% | 95 |
6 | CPG OLIGONUCLEOTIDE | authKW | 397567 | 3% | 52% | 44 |
7 | SECT RETROVIRAL IMMUNOL | address | 362427 | 2% | 59% | 35 |
8 | CPG | authKW | 325337 | 6% | 17% | 107 |
9 | TOLL LIKE RECEPTOR 9 | authKW | 269992 | 3% | 26% | 59 |
10 | IMMUNOSTIMULATORY DNA | authKW | 196384 | 1% | 75% | 15 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Immunology | 22775 | 54% | 0% | 950 |
2 | Medicine, Research & Experimental | 2282 | 14% | 0% | 251 |
3 | Allergy | 1097 | 4% | 0% | 68 |
4 | Oncology | 386 | 10% | 0% | 170 |
5 | Pharmacology & Pharmacy | 228 | 9% | 0% | 162 |
6 | Cell Biology | 210 | 8% | 0% | 134 |
7 | Veterinary Sciences | 159 | 4% | 0% | 78 |
8 | Biochemistry & Molecular Biology | 143 | 12% | 0% | 214 |
9 | Biotechnology & Applied Microbiology | 137 | 5% | 0% | 92 |
10 | Hematology | 116 | 3% | 0% | 58 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | SECT RETROVIRAL IMMUNOL | 362427 | 2% | 59% | 35 |
2 | SECT RETROVIRAL | 162481 | 1% | 85% | 11 |
3 | BIOPHARMACEUT DRUG METAB | 134612 | 2% | 21% | 36 |
4 | SAM ROSE STEIN AGING | 85888 | 2% | 15% | 32 |
5 | VACCINE INFECT DIS ORG | 39923 | 2% | 8% | 30 |
6 | SECT RADIAT MED | 39277 | 0% | 75% | 3 |
7 | MED MICROBIOL IMMUNOL HYG | 37320 | 2% | 5% | 43 |
8 | FDN MOL BIOL BIOINFORMAT | 36363 | 0% | 42% | 5 |
9 | COLEY PHARMACEUT GRP | 34914 | 0% | 100% | 2 |
10 | ERATO MICROBIAL DIS | 34914 | 0% | 100% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT | 15170 | 1% | 5% | 18 |
2 | JOURNAL OF IMMUNOLOGY | 8743 | 9% | 0% | 165 |
3 | VACCINE | 7896 | 5% | 1% | 91 |
4 | NUCLEIC ACID THERAPEUTICS | 6854 | 1% | 4% | 10 |
5 | SPRINGER SEMINARS IN IMMUNOPATHOLOGY | 6712 | 1% | 2% | 17 |
6 | OLIGONUCLEOTIDES | 6470 | 1% | 4% | 10 |
7 | INTERNATIONAL IMMUNOPHARMACOLOGY | 4349 | 2% | 1% | 33 |
8 | VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY | 4076 | 2% | 1% | 36 |
9 | EUROPEAN JOURNAL OF IMMUNOLOGY | 3659 | 3% | 0% | 53 |
10 | CURRENT OPINION IN MOLECULAR THERAPEUTICS | 2398 | 1% | 1% | 11 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CPG ODN | 1459238 | 10% | 48% | 173 | Search CPG+ODN | Search CPG+ODN |
2 | CPG MOTIF | 1088779 | 6% | 58% | 108 | Search CPG+MOTIF | Search CPG+MOTIF |
3 | CPG DNA | 914026 | 5% | 55% | 96 | Search CPG+DNA | Search CPG+DNA |
4 | CPG OLIGODEOXYNUCLEOTIDES | 878242 | 5% | 59% | 86 | Search CPG+OLIGODEOXYNUCLEOTIDES | Search CPG+OLIGODEOXYNUCLEOTIDES |
5 | TLR9 | 438717 | 5% | 26% | 95 | Search TLR9 | Search TLR9 |
6 | CPG OLIGONUCLEOTIDE | 397567 | 3% | 52% | 44 | Search CPG+OLIGONUCLEOTIDE | Search CPG+OLIGONUCLEOTIDE |
7 | CPG | 325337 | 6% | 17% | 107 | Search CPG | Search CPG |
8 | TOLL LIKE RECEPTOR 9 | 269992 | 3% | 26% | 59 | Search TOLL+LIKE+RECEPTOR+9 | Search TOLL+LIKE+RECEPTOR+9 |
9 | IMMUNOSTIMULATORY DNA | 196384 | 1% | 75% | 15 | Search IMMUNOSTIMULATORY+DNA | Search IMMUNOSTIMULATORY+DNA |
10 | OLIGODEOXYNUCLEOTIDE | 156922 | 3% | 16% | 58 | Search OLIGODEOXYNUCLEOTIDE | Search OLIGODEOXYNUCLEOTIDE |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | KRIEG, AM , (2002) CPG MOTIFS IN BACTERIAL DNA AND THEIR IMMUNE EFFECTS.ANNUAL REVIEW OF IMMUNOLOGY. VOL. 20. ISSUE . P. 709 -760 | 163 | 60% | 1613 |
2 | KRIEG, AM , (2006) THERAPEUTIC POTENTIAL OF TOLL-LIKE RECEPTOR 9 ACTIVATION.NATURE REVIEWS DRUG DISCOVERY. VOL. 5. ISSUE 6. P. 471-484 | 123 | 65% | 624 |
3 | VOLLMER, J , KRIEG, AM , (2009) IMMUNOTHERAPEUTIC APPLICATIONS OF CPG OLIGODEOXYNUCLEOTIDE TLR9 AGONISTS.ADVANCED DRUG DELIVERY REVIEWS. VOL. 61. ISSUE 3. P. 195 -204 | 109 | 63% | 215 |
4 | WILSON, HL , DAR, A , NAPPER, SK , LOPEZ, AM , BABIUK, LA , MUTWIRI, GK , (2006) IMMUNE MECHANISMS AND THERAPEUTIC POTENTIAL OF CPG OLIGODEOXYNUCLEOTIDES.INTERNATIONAL REVIEWS OF IMMUNOLOGY. VOL. 25. ISSUE 3-4. P. 183 -213 | 122 | 77% | 36 |
5 | JURK, M , VOLLMER, J , (2007) THERAPEUTIC APPLICATIONS OF SYNTHETIC CPG OLIGODEOXYNUCLEOTIDES AS TLR9 AGONISTS FOR IMMUNE MODULATION.BIODRUGS. VOL. 21. ISSUE 6. P. 387-401 | 126 | 65% | 50 |
6 | BODE, C , ZHAO, G , STEINHAGEN, F , KINJO, T , KLINMAN, DM , (2011) CPG DNA AS A VACCINE ADJUVANT.EXPERT REVIEW OF VACCINES. VOL. 10. ISSUE 4. P. 499-511 | 83 | 62% | 172 |
7 | WANG, H , RAYBURN, E , ZHANG, RW , (2005) SYNTHETIC OLIGODEOXYNUCLEOTIDES CONTAINING DEOXYCYTIDYL-DEOXYGUANOSINE DINUCLEOTIDES (CPG ODNS) AND MODIFIED ANALOGS AS NOVEL ANTICANCER THERAPEUTICS.CURRENT PHARMACEUTICAL DESIGN. VOL. 11. ISSUE 22. P. 2889-2907 | 109 | 77% | 26 |
8 | UHLMANN, E , VOLLMER, J , (2003) RECENT ADVANCES IN THE DEVELOPMENT OF IMMUNOSTIMULATORY OLIGONUCLEOTIDES.CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT. VOL. 6. ISSUE 2. P. 204-217 | 108 | 78% | 54 |
9 | MANUJA, A , MANUJA, BK , KAUSHIK, J , SINGHA, H , SINGH, RK , (2013) IMMUNOTHERAPEUTIC POTENTIAL OF CPG OLIGODEOXYNUCLEOTIDES IN VETERINARY SPECIES.IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. VOL. 35. ISSUE 5. P. 535-544 | 90 | 72% | 2 |
10 | MUTWIRI, GK , NICHANI, AK , BABIUK, S , BABIUK, LA , (2004) STRATEGIES FOR ENHANCING THE IMMUNOSTIMULATORY EFFECTS OF CPG OLIGODEOXYNUCLEOTIDES.JOURNAL OF CONTROLLED RELEASE. VOL. 97. ISSUE 1. P. 1-17 | 99 | 70% | 86 |
Classes with closest relation at Level 1 |